Benito Novas, Global Stem Cells Group CEO Announces Opening of New Stem Cell Center in Valencia, Spain
The new center will continue the Global Stem Cells Group’s mission to expand access to stem cell therapies and training to physicians across the globe.
MIAMI LAKES, Florida—A new Stem Cell Center is set to open its doors in Spain. Benito Novas, CEO of the Global Stem Cells Group (GSCG), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has announced the opening of the group’s Valencia, Spain center. The new clinic will be the group’s third operation in Spain and the fourth in Europe.
The Global Stem Cells Group’s Valencia center joins the already existing centers in , which include locations in Bruselas, Madrid, and Barcelona. With the opening of the new center, the GSCG will boast 41 such locations across the globe.
Novas noted that the group has been focusing its efforts on opening its cutting-edge Stem Cell Centers in Europe, in part due to the group’s recognition that regenerative medicine is a fast-growing field across the continent.
“We are pleased to be able to open the doors on a new Stem Cells Center in Europe,” noted Novas. “The GSCG is continually exploring opportunities to deliver new stem-cell based treatment options to patients across Europe, and the Valencia center gives us the opportunity to do this while meeting our strategic mission to expand our presence in Europe.”
In opening the new center, the GSCG has signed an agreement with Dra. Laura Maria Caicedo, medical director of the Instituto Valenciano MEDEC (https://medec.es/conoce-medec/#equipoMedico). Dr. Caicedo is a specialist on hair loss with an interest in delivering stem cell based treatments to her patients and others in Valencia.
“I am thrilled to lead the efforts at the Stem Cell Center in Valencia,” said Dra. Caicedo. “I am looking forward to utilizing cutting-edge therapy options based in stem cell science to help treat patients suffering from hair loss. Additionally, the opportunity is an exciting one given the Global Stem Cells Group’s excellent reputation and stature as the longest-standing and most respected stem cells network. I’m looking forward to learning from other physicians in the network across the globe and sharing my expertise with other practitioners in regenerative medicine.”
The GSCG will provide the Valencia center with the newest and most effective marketing tools in the field to help the franchise increase its performance in recruiting new patients.
Marketing support is one of the many benefits of joining the GSCG’s expanding global network of clinics. Being part of the group’s network gives physicians access to other experts within the its global network, add to their practice the newest regenerative medicine protocols, and have access to a proven marketing strategy developed by GSCG.
To learn more about the Global Stem Cells Group, visit http://www.stemcellsgroup.com/.
The global group will hold its 6th International Regenerative Medicine Symposium in October 2019.
MIAMI LAKES, Florida—The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has announced its 6th annual International Regenerative Medicine Symposium in Buenos Aires. The event will attract physicians from across the globe and will be held on October 12, 2019 in Buenos Aires, Argentina at the Hotel Panamericano.
The past five years of the ISSCA sponsored event have been a global success. This year’s meeting will feature educational sessions and product information and demonstrations, with a special focused placed on the newest compounds in the allogeneic stem cells market, including exosomes, amniotic fluid compounds, and cord blood products. With allogeneic compounds growing in popularity, safety, and treatment efficacy, ISSCA will give physicians the opportunity to learn more about them and how they can be incorporated into their practices.
A number of experts within the field of regenerative medicine are confirmed for the event and include.
• Dra. Maritza Novas, Chief of I&D, Global Stem Cells Group USA
• Dr. Leopoldo Paradas, President of Asociación Chilena de Ingeniería Tisular
• Dr. Matias Fernandez Vina Argentinian Cardiologist
“We are pleased to be hosting our popular International Regenerative Medicine Symposium for a sixth year,” said Benito Novas, CEO of ISSCA. “Each year our symposium focuses on critical topics and exciting breakthroughs in the field of regenerative medicine, and this year is no different as we seek to retain our position as a vanguard in the field.”
Physicians interested in registering for or learning more about the Buenos Aires symposium may visit https://www.issca.us/.
The newly developed program gives physicians the opportunity to learn the latest methods and knowledge in the field of regenerative medicine.
MIAMI LAKES, Florida—The International Society for Stem Cells Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has announced a new course for physicians interested in gaining certification in regenerative medicine. The course was developed out of the group’s highly successful global conference certifications, providing physicians a newly designed and more intimate and personalized smaller group training through which to gain critical skills and knowledge in the field of regenerative medicine.
Through completion of the certification course, physicians will learn how they can add cell-based product protocols to their existing medical practices, including those using exosomes, amniotic fluid, and cord blood.
A host of global experts practicing within the field will be on hand to lead attendees through the new training. They will share first-hand scientific information on the science behind cell therapies and cell-based products and their clinical applications. In-depth examination of clinical trials that demonstrate the safety and efficacy of cell-based products will also be part of the one-day training.
Physicians attending the certification will also learn how to distinguish between the most popular cellular products on the market and what factors to keep in mind when choosing stem cell protocols as a therapeutic alternative. Course faculty will additionally lead attendees through how to structure treatment plans and protocols for patients who may benefit from stem cell therapies.
“We are pleased to be able to offer this exciting and informative new training to physicians interested in adding stem cell treatment options to their current medical practices,” said Benito Novas, CEO of ISSCA. “We seek to remain at the forefront of the stem cells field by continuously innovating and offering the global community the training they need to deliver effective, cutting edge treatment options to their patients. We decided to offer this new training in part due to the demand for it from our customers, who are eager to expand their knowledge base and offer new treatment options to their patients.”
ISSCA has set four dates and locations for its new certification course, and this is the first time such certification has been held by the group outside of the United States:
• Santiago de Chile, Chile: September 5, 2019
• Bogota, Colombia: October 4, 2019
• Buenos Aires, Argentina: October 11, 2019
• Miami, Florida (in English): November 1, 2019
To learn more about ISSCA’s latest certification program and to register, or to learn more about ISSCA, visit https://www.issca.us/.
CES University of Medellín, Colombia bestowed the honor upon Novas due to his exemplary work in marketing and the regenerative medicine field
MIAMI LAKES, Florida—Benito Novas, Vice President of The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has been awarded the degree of Dr. Honoris Causa from CES University in Medellín. The award comes in recognition of his work as a global leader in marketing and as a key figure in the regenerative medicine field.
For the past 15 years, Novas has worked as a marketing professional and is a recognized leader in the industry. Novas created a specific marketing model that has proven to be successful for private medical institutions to gain industry recognition and grow into thriving organizations. He is a sought-after speaker and has been an invited guest and keynote speaker at a number of medical congresses across the globe, sharing his latest marketing strategies with medical institutions looking to recruit new patients.
Novas has also played an integral role in the regenerative medicine field as a business owner. His contributions to the field are noteworthy and include organizing various congresses and certification courses across five continents. His holding, the Global Stem Cells Group, has worked to increase access to affordable equipment and regenerative medicine supplies to doctors across the world. His foundation has provided hundreds of free regenerative medicine treatments in each country where he has visited.
“It is an honor to have such a prestigious award bestowed upon me” said Novas. “I am grateful to the administration at CES University for considering me for this award.”
Global Stem Cells’ group affiliate Adimarket set to launch new products during the international event.
MIAMI LAKES, Florida—The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, will host a two-day medical congress in Cancun, Mexico. The 7 Congreso Internacional de Terapias Avanzadas en Medicina will take place on December 7-8, 2019 and will feature speakers from various countries, including the United States, Argentina, Mexico, and Colombia.
Congress organizers expect over 250 Mexican doctors will attend the event, which will feature a variety of experts in the field of regenerative medicine and cutting-edge products in the industry that are designed to help treat patients suffering from degenerative diseases.
Adimarket, the largest online regenerative medicine store and a subsidiary of the Global Stem Cells Group, will be on hand to launch its newest allogeneic stem cells products during the event. These heterologous compounds were developed exclusively for a LATAM market, striking a balance between a high-quality treatment option and an affordable price. Products currently offered by Adimarket in this category include exosomes, cord blood derived stem cells, and stem cells derived from amniotic fluid.
All of Adimarket’s products are designed to help provide safe and effective treatment options to doctors treating patients suffering from degenerative diseases.
To learn more about Adimarket and all of its regenerative medicine solutions, visit https://www.adimarket.net/. To learn more about ISSCA and all of their upcoming and past events, visit https://issca.us/.
The ongoing partnership will offer certification in regenerative medicine for European-based medical practitioners .
MIAMI LAKES, Florida—The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has signed an agreement with European-based Clinica Planas to offer a stem cells certification training program. The first event will be held in Barcelona on October 18-19, 2019.
“The Global Stem Cells Group is pleased to partner with Clinica Planas to offer this important certification in cell therapies,” said Benito Novas, Vice President of the Global Stem Cells Group. “This partnership will continue our mission to help provide knowledge of regenerative medicine practices and treatment options to physicians across the globe.”
Clinica Planas has two locations in Spain—Barcelona and Madrid—and is known as one of the most prestigious medical centers in Europe. In this new deal, Clinical Planas will partner with the Global Stem Cells Group to help train European-based physicians in the regenerative medicine industry’s best practices and most up-to-date knowledge.
The inaugural certification workshop will be held on October 11-12 in Barcelona, with additional certification opportunities to be offered on an ongoing basis in the future. During the two-day event, physicians will receive insight on 22 proprietary treatment protocols to treat degenerative diseases, acquire skills to be able to offer alternative treatment options to patients who have yet to try regenerative medicine as an option, and join an exclusive network of doctors at the forefront of medical science.
“Our goal is to help physicians looking for new treatment options for their patients suffering from degenerative diseases gain the necessary skills to be able to offer regenerative treatments as an option to alleviate their patients’ suffering,” Novas noted.
To learn more about the October 2019 certification event in Barcelona, visit http://cursocelulasmadre.com/entrenamiento-en-barcelona/.
MIAMI LAKES, FL, May 30, 2019-Global Stem Cells Group Inc. (GSCG) is pleased to announce that it has entered into a binding letter of intent to sell 100% to Lans Holdings Inc. (OTCPink: LAHO)
GSCG operates in the global stem cell market which is forecasted by Transparency Market Research to reach $270 billion dollars by 2025 of which roughly 40% or $100 billion will be derived from outside of North America and growing at a 13.8% compounded annual growth rate.
GSCG specializes in leading-edge stem cell research, patient application and physician training. The company licenses its name and intellectual property to physicians around the world and supplies them with necessary equipment and medical supplies to perform stem cell treatments. The company currently has one of the largest member clinic networks in the world spanning over 25 countries.
“We are very pleased to have entered into this binding LOI with Global Stem Cells Group,” said Dave Christensen, CEO of Lans Holdings Inc. “This transaction represents a significant opportunity for our company to enter the explosive field of Stem Cell technology with a proven and seasoned team and I look forward to working closely with GSCG to execute on their growth plans.”
“We are excited to join forces with Lans Holdings,” said Benito Novas, President and CEO of Global Stem Cells Group. “This union will allow us to have access to the capital markets to further fuel our growth as the global stem cells market enters into an accelerated expansion phase.”
Novas is a global expert on medical practice marketing strategies, specifically those pertaining to regenerative medicine.
MIAMI LAKES, Florida—Benito Novas, CEO of the Global Stem Cells Group, will serve as the keynote speaker at an event sponsored by the International Society for Stem Cell Application held in Mexico City on May 3-4, 2019. Novas is known as a global experts on medical practice marketing strategies, specifically those pertaining to the regenerative medicine field.
The Mexico City Stem Cells Seminar is a two-day medical congress and the first of its kind to offer an entire day focused on medical marketing. Novas will serve as both a keynote speaker and also as a marketing professional to offer his expertise during this portion of the congress.
As the CEO of the Global Stem Cells Group, Benito Novas is an entrepreneur and leader of an international enterprise that provides complete services to the regenerative medicine industry. Though his work, he has created programs that provide Stem Cells Certification opportunities for practitioners in the field in addition to supporting stem cells medical research efforts across the globe.
Benito Novas is known as a global expert on research marketing strategies, especially pertaining to the realm of regenerative medicine. He has extensively researched marketing strategies that are proven to grow medical practices worldwide, including those in the US. Putting his research to use, Novas has successfully grown regenerative medical practices across the globe.
In addition to his personal research pursuits, Benito Novas frequently lends his expertise as a marketing expert to private medical practices and other groups worldwide. He has also conducted medical business in various countries across South America and the Middle East.
To learn more about Benito Novas, visit his LinkedIn profile at https://bit.ly/2IMgGtJ.
Cancun Stem Cells Center Offers Hope for US Patients Suffering from Degenerative or Chronic Diseases
Free from US regulatory constraints, the center offers stem cells protocols needed to effectively treat a wide variety of disease.
MIAMI LAKES, Florida—For physicians based in the United States looking for high-quality patient care in the realm of regenerative medicine, the Stem Cells Center in Cancun, Mexico offers a cutting-edge care solution outside of the US. The Cancun center is a member of the Global Stem Cells Group network, which is comprised of a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology and regenerative medicine.
A number of conditions that patients present may require physicians to use treatment methods that will increase the cell counts that are delivered during the protocol. For patients suffering from chronic degenerative conditions or disorders based in genetics, physicians may need to culture expanded autologous cells. Currently, autologous stem cell expansion conducted in labs before being reintroduced into patients is not a viable treatment option in the US due to regulatory constraints. Thus, both the patient and physician are left turning to less effective treatment options using only cells obtained in the medical office.
For patients suffering from some degenerative conditions, more involved methods of therapy and more aggressive ways of deploying cells may be necessary than current US regulations allow. To deploy these more aggressive forms of treatment, catheterization is ideal. To perform intricate catheterizations of the carotid artery and the vascular arteries of the brain, for instance, it is critical to have a properly staffed and equipped hospital to perform the procedure. A hemodynamics suite and having an intensive care unit nearby are essential tenets of such treatment protocols.
Patients requiring more aggressive and effective treatment options for degenerative and chronic diseases can receive the treatment they need at the Stem Cell Center in Cancun. Because the facility is located outside of the US, patients and physicians are not bound by regulatory limitations affecting lab-expanded autologous cells.
The Global Stem Cells Groups’ facility in Cancun is a Level 3 hospital equipped with an intensive care operating room and a hemodynamics suite ideal for patients needing critical treatments using regenerative medicine. Hospital staff includes a highly-ranked, high-level specialist in the area of regenerative medicine. Current facility protocols are in place to cater to patients needing the facility’s specialized services, and the hospital is associated with a local laboratory that can easily provide the amount of allogeneic cells needed for treatments requiring them.
Physicians with patients who may benefit from the medical services offered at the Stem Cells Center in Cancun are invited to reach out to set up a meeting to learn more about what services the facility offers and how to access the center for treatment. To learn more about the Global Stem Cells Group and the Cancun facility, visit http://www.stemcellsgroup.com/.
One of the treatments that the FDA approved for knee arthritis is a Hyalronic Acid (HA) injection, sometimes also known as Viscosupplementation. It has been incredibly successful for knee arthritis. In fact, so successful that many physicians are starting to use it on other parts of the body, like the hip and shoulder, which the FDA does not approve of.
HA, when injected, works like the fluid that naturally surrounds your joints. This fluid can be like a lubricant for your joints, and absorb shock, allowing bones that otherwise cause arthritis pain cause much less. Over time, it is even absorbed into the joint, which can cause the body to create a more stable cartilage all on its own.
The evidence for this treatment is astounding, with a systematic review of 76 trials, all of which were randomized controller trials. The review noted that HA, when injected, can benefit function, reduce pain, and can be a reliable and effective treatment for knee osteoarthritis.
On the other hand, there is PRP therapy. Platelet Rich Plasma, or PRP, which is a type of blood that has 6 to 10 times more platelets than what is normally found in blood. They even contain many growth factors, such as Epidermal Growth Factor, Connective Tissue Growth Factor, and many more. These can help heal injured parts of the body by using the bodies natural healing tools.
However, PRP is not regulated by the FDA, and devices that are used to make PRP require said approval. Aside from this, multiple studies shoe that PRP can be very effective in the treatment of tendon injuries, as well as for osteoarthritis. This treatment can even help in the reduction of pain. There are even more studies being conducted on whether it can help other things, such as hair regrowth, cardiac muscle repair, and even dermatologic rejuvenation.
So should you use HA injections, or PRP?
In many studies, PRP has bee demonstrated to work just as well, if not better than HA. HA is also only FDA approved for the knee, meaning that it is not approved or covered for the use in any other joint. Also, the risk of infection and rejection is far less while using PRP, as it is a substance that comes from your own body, and contains white blood cells, which can help fight infection.
PRP also saves money in the long run, as using HA in a joint other than the knee is not FDA approved or covered by insurance. As a result, it can cost your patient 1500$ or more. This can even be on top of various other charges, such as doctors visits, and even the injection itself. PRP, on the other hand, only costs from 800 to 1200$ out of pocket.
So PRP has been demonstrated to be just as effective, if not better, than HA injections when it comes to arthritis pain. It does not pose a risk for infection or and auto-immune reaction either, and is even far cheaper than HA. So picking which one to use should be a no-brainer.